Panacea Biotec informs about updates

17 May 2021 Evaluate

Panacea Biotec has informed that the Company has instituted a suit before the Hon'ble Delhi High Court seeking to restrain Sanofi Healthcare India from marketing a fully liquid hexavalent vaccine that would infringe Company's patent for its fully liquid Whole Cell Pertussis based fully liquid Hexavalent Vaccine, EasySix. Panacea Biotec's EasySix is a first of its kind Whole Cell Pertussis based fully liquid Hexavalent Vaccine which comes in a pre-filled syringe and is used to vaccinate against, Diphtheria, Tetanus, Whooping Cough, Hepatitis B, Haemophilus influenza type b and Inactivated Polio (DTwP-HepB-Hib-IPV). EasySix has been in the market since 2017. A brief note in respect of the above-mentioned matter is enclosed for information and record.

The above information is a part of company’s filings submitted to BSE.

Panacea Biotec Share Price

364.20 -4.40 (-1.19%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×